Efficacy of prothrombin complex concentrate (PCC) versus fresh frozen plasma (FFP) in reducing perioperative blood loss in cardiac surgery: study protocol for a non-inferiority, randomised controlled trial

Lijian Pei, Chen Sun, Hong Lv, Yuelun Zhang, Jia Shi, Lijian Pei, Chen Sun, Hong Lv, Yuelun Zhang, Jia Shi

Abstract

Objective: To explore whether prothrombin complex concentrate (PCC) is not inferior to fresh frozen plasma (FFP) with regard to reducing perioperative blood loss in patients undergoing cardiac surgery under cardiopulmonary bypass (CPB).

Setting: Fu Wai Hospital, and Peking Union Medical College Hospital in China.

Participants: Patients undergoing elective coronary artery bypass grafting, valve replacement or valvuloplasty under CPB, between 18 and 80 years old, will be included.

Design: This study is a non-inferiority, randomised controlled clinical trial. A total of 594 subjects will be randomly assigned to two groups (group PCC and group FFP) and given corresponding interventions when at least one of the following criteria is met: (1) international normalised ratio >1.7 measured 20 min after CPB, (2) prolonged prothrombin time or activated partial thromboplastin time (>1.5 times baseline) measured 20 min after CPB and (3) excessive bleeding observed. 4-factor PCC (15 IU/kg) and FFP (10 mL/kg) will be given to group PCC and group FFP, respectively. Preoperative management, anaesthetic and surgical techniques will be standardised for both groups.

Primary and secondary outcome measures: The primary outcome is the volume of blood loss during and within 24 hours after surgery. The secondary outcomes include (1) the total units of allogeneic red blood cells transfused during and within 7 days after surgery, (2) re-exploration due to postoperative bleeding within 7 days after surgery, (3) adverse events and serious adverse events within 30 days after surgery and (4) length of intensive care unit stay and hospital stay.

Trial registration number: Registered under NCT04244981 at ClinicalTrials.gov on 28 January 2020, https://ichgcp.net/clinical-trials-registry/NCT04244981?cond=NCT04244981&draw=2&rank=1.

Ethics and dissemination: This study has been approved by the Institutional Review Board of Peking Union Medical College Hospital (ZS-2242).

Keywords: anaesthesia in cardiology; cardiac surgery; clinical trials.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study design and participant flow chart. FFP, fresh frozen plasma; PCC, prothrombin complex concentrate.
Figure 2
Figure 2
Study period. APTT, activated partial thromboplastin time; FFP, fresh frozen plasma; INR, international normalised ratio; PCC, prothrombin complex concentrate; PT, prothrombin time; RBC, red blood cell.

References

    1. Parr KG, Patel MA, Dekker R, et al. . Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth 2003;17:176–81. 10.1053/jcan.2003.44
    1. Görlinger K, Shore-Lesserson L, Dirkmann D, et al. . Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth 2013;27:S20–34. 10.1053/j.jvca.2013.05.014
    1. Christensen MC, Krapf S, Kempel A, et al. . Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg 2009;138:687–93. 10.1016/j.jtcvs.2009.02.021
    1. Ferraris VA, Hochstetler M, Martin JT, et al. . Blood transfusion and adverse surgical outcomes: the good and the bad. Surgery 2015;158:608–17. 10.1016/j.surg.2015.02.027
    1. Likosky DS, Zhang M, Paone G, et al. . Impact of institutional culture on rates of transfusions during cardiovascular procedures: the Michigan experience. Am Heart J 2016;174:1–6. 10.1016/j.ahj.2015.12.019
    1. Murphy GJ, Pike K, Rogers CA, et al. . Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 2015;372:997–1008. 10.1056/NEJMoa1403612
    1. Robich MP, Koch CG, Johnston DR, et al. . Trends in blood utilization in United States cardiac surgical patients. Transfusion 2015;55:805–14. 10.1111/trf.12903
    1. Dyke C, Aronson S, Dietrich W, et al. . Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg 2014;147:1458–63. 10.1016/j.jtcvs.2013.10.070
    1. Ranucci M, Baryshnikova E, Castelvecchio S, et al. . Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg 2013;96:478–85. 10.1016/j.athoracsur.2013.03.015
    1. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. . Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of thoracic surgeons and the Society of cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007;83:S27–86. 10.1016/j.athoracsur.2007.02.099
    1. Höfer J, Fries D, Solomon C, et al. . A snapshot of coagulopathy after cardiopulmonary bypass. Clin Appl Thromb Hemost 2016;22:505–11. 10.1177/1076029616651146
    1. Kaspereit F, Hoffmann S, Pragst I, et al. . Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model. Br J Anaesth 2010;105:576–82. 10.1093/bja/aeq216
    1. Raleigh L, Cole SP. Con: factor concentrate usage in cardiac surgery-a paucity of data limits their universal adoption. J Cardiothorac Vasc Anesth 2018;32:1068–71. 10.1053/j.jvca.2017.05.005
    1. Bhatt HV, Subramaniam K. Pro: prothrombin complex concentrate should be used in preference to fresh frozen plasma for hemostasis in cardiac surgical patients. J Cardiothorac Vasc Anesth 2018;32:1062–7. 10.1053/j.jvca.2017.05.044
    1. Sarode R, Milling TJ, Refaai MA, et al. . Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIB study. Circulation 2013;128:1234-43. 10.1161/CIRCULATIONAHA.113.002283
    1. Goldstein JN, Refaai MA, Milling TJ, et al. . Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3B, open-label, non-inferiority, randomised trial. Lancet 2015;385:2077–87. 10.1016/S0140-6736(14)61685-8
    1. Demeyere R, Gillardin S, Arnout J, et al. . Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010;99:251–60. 10.1111/j.1423-0410.2010.01339.x
    1. Cappabianca G, Mariscalco G, Biancari F, et al. . Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care 2016;20:20–5. 10.1186/s13054-015-1172-6
    1. Song HK, Tibayan FA, Kahl EA, et al. . Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg 2014;147:1036–40. 10.1016/j.jtcvs.2013.11.020
    1. Weinberger J, Cipolle M. Optimal reversal of novel anticoagulants in trauma. Crit Care Clin 2017;33:135–52. 10.1016/j.ccc.2016.08.005
    1. Arnékian V, Camous J, Fattal S, et al. . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg 2012;15:382–9. 10.1093/icvts/ivs224
    1. Ortmann E, Besser MW, Sharples LD, et al. . An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 2015;121:26–33. 10.1213/ANE.0000000000000689
    1. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. . Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:270–382. 10.1097/EJA.0b013e32835f4d5b
    1. Tibi P, McClure RS, Huang J, et al. . STS/SCA/AmSECT/SABM update to the clinical practice guidelines on patient blood management. J Cardiothorac Vasc Anesth 2021;35:2569–91. 10.1053/j.jvca.2021.03.011
    1. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010;8:149–54. 10.2450/2010.0149-09
    1. Vigué B, Ract C, Tremey B, et al. . Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007;33:721–5. 10.1007/s00134-007-0528-z
    1. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008;109:918–26. 10.1097/ALN.0b013e3181895bd8
    1. Wong JK, Chen PC, Falvey J, et al. . Anticoagulation reversal strategies for left ventricular assist device patients presenting with acute intracranial hemorrhage. Asaio J 2016;62:552–7. 10.1097/MAT.0000000000000404
    1. Cosgrove RH, Patanwala AE, Sears BL, et al. . The use of three factor prothrombin complex concentrate to reverse warfarin treated mechanical circulatory device patients immediately prior to heart transplant. J Heart Lung Transplant 2015;34:S54–5. 10.1016/j.healun.2015.01.135
    1. Pagano D, Milojevic M, Meesters MI, et al. . 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018;53:79–111. 10.1093/ejcts/ezx325
    1. Arnékian V, Camous J, Fattal S, et al. . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg 2012;15:382–9. 10.1093/icvts/ivs224
    1. Green L, Roberts N, Cooper J, et al. . Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia 2021;76:892–901. 10.1111/anae.15327
    1. Ansell J, Hirsh J, Hylek E. Pharmacology and management of the vitamin K antagonists: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133. 10.1378/chest.08-0670
    1. Dentali F, Marchesi C, Giorgi Pierfranceschi M, et al. . Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011;106:429–38. 10.1160/TH11-01-0052

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere